COVID-19 Antiviral Agents and COVID-19 Rebound
Expert discussion of landmark clinical trials of COVID-19 antivirals for nonhospitalized patients and the COVID-19 rebound phenomenon.
Decera Clinical Education Infectious Disease Podcast · Jason Gallager PharmD, Emily Heil PharmD MS BCIDP AAHIVP
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Jason Gallagher, PharmD, and Emily Heil, PharmD, MS, BCIDP discuss landmark clinical trials of COVID-19 antivirals for nonhospitalized patients and COVID-19 rebound phenomenon, including:
- EPIC-HR study of nirmatrelvir plus ritonavir
- PINETREE study of remdesivir
- MOVe-OUT and Panoramic studies of molnupiravir
- COVID-19 rebound in treated and untreated patients
Presenters:
Jason Gallagher, PharmD
Clinical Professor
School of Pharmacy
Temple University
Clinical Pharmacy Specialist
Infectious Diseases
Temple University Hospital
Philadelphia, Pennsylvania
Emily Heil, PharmD, MS, BCIDP, AAHIVP
Associate Professor
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Infectious Diseases Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.